A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Single Injection LC28-0126 Immediately Before PCI (Percutaneous Coronary Intervention) in Patients With STEMI(ST-segment Elevation Myocardial Infarction)
Phase of Trial: Phase II
Latest Information Update: 13 May 2016
Price : $35 *
At a glance
- Drugs LC28 0126 (Primary)
- Indications Myocardial infarction
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 31 Aug 2018 Biomarkers information updated
- 08 May 2016 Status changed from active, no longer recruiting to completed.
- 17 Sep 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.